NewsBenzingaCervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain Benzinga 2026.10.12 11:36 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
